DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus

Journal of Virology

Volumn 75, Issue 17, 2001, Pages 7882-7892

  Garber, A C ^a   Shu, M A ^a   Hu, J ^a   Renne, R ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATENCY ASSOCIATED NUCLEAR ANTIGEN; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CARBOXY TERMINAL SEQUENCE; DNA BINDING; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TRANSCRIPTION REGULATION; VIRUS GENOME; VIRUS LATENCY;

ANIMALS; ANTIGENS, VIRAL; BINDING SITES; CELL LINE; DNA, VIRAL; DNA-DIRECTED RNA POLYMERASES; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; HERPESVIRUS 8, HUMAN; HUMANS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); TERMINAL REPEAT SEQUENCES; TRANSCRIPTION, GENETIC; TRANSFECTION; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 0034870212     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.17.7882-7892.2001     Document Type: Article

References (56)

1. Epstein-Barr virus infections
2. Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus DNA
3. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells
4. DNA sequence and expression of the B95-8 Epstein-Barr virus genome
5. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen
6. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (tr) sequence and specifically binds DNA
7. Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma
8. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas
9. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
10. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) binds ATF4/Creb2 and inhibits its transcriptional activation activity
11. The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells
12. Fas-induced proteolytic activation and intracellular redistribution of the stress-signaling kinase MEKK1
13. A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus
14. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma
15. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary, effusion lymphoma
16. Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma
17. p53 inhibition by the LANA protein of KSHV protects against cell death
18. An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene
19. Molecular polymorphism of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen: Evidence for a large repertoire of viral genotypes and dual infection with different viral genotypes
20. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J. kappa
21. Differential regulation of the overlapping Kaposi's sarcoma-associated herpesvirus vGCR (orf74) and LANA (orf73) promoters
22. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus
23. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission
24. Identification of a major latent nuclear antigen. LNA-1, in the human herpesvirus 8 genome
25. Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8
26. Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells
27. The structure and coding organization of the genomic termini of Kaposi's sarcoma-associated herpesvirus
28. EBNA-1: A protein pivotal to latent infection by Epstein-Barr virus
29. Epstein-Barr virus
30. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1
31. The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein
32. Multiple regions within EBNA1 can link DNAs
33. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV
34. Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma
35. Product review. New mammalian expression vectors
36. Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene
37. DNA binding activity is required for EBNA 1-dependent transcriptional activation and DNA replication
38. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines
39. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells
40. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen
41. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region
42. Trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen I
43. Modulation of cellular and viral transcription by the latency-associated nuclear antigen (LANA/ORF73) of Kaposi's sarcoma-associated herpesvirus
44. Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells
45. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture
46. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHVS)
47. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines
48. Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies
49. Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein
50. Identification of minimal oriP of Epstein-Barr virus required for DNA replication
51. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells
52. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection
53. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells
54. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma